Redox and Cancer Part A

Erscheinungsjahr 2014
ISBN: 978-0-12-420117-0
Verlag: William Andrew Publishing

Buch, Englisch, 338 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 750 g

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics — Volume 122 explores subjects related to redox, including: redox homeostasis in epithelial-derived cancers; reactive oxygen species in normal and tumor stem cells; and gamma-glutamyl transpeptidase and redox regulation.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Townsend, Danyelle

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. Reactive Oxygen Species in Normal and Tumor Stem Cells
2. Emerging Regulatory Paradigms in Glutathione Metabolism
3. Gamma-Glutamyl Transpeptidase: Redox Regulation and Drug Resistance
4. Pleiotropic Functions of Glutathione S-Transferase P
5. A Comparison of Reversible versus Irreversible Protein Glutathionylation
6. Glutathione Transferases in the Bioactivation of Azathioprine
7. Thioredoxin and Hematological Malignancies
8. Role of the Keap1-Nrf2 Pathway in Cancer

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.